Molecule News and Research

RSS

Cedars-Sinai opens Phase III clinical trial for patients with intestinal carcinoid cancer

Working to improve treatment and survivorship outcomes, the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a Phase III clinical trial of targeted radiation for patients with intestinal carcinoid cancer that has spread beyond the intestine.

10 Jun 2013

Researchers mobilize brain's native stem cells to replenish neuron lost in Huntington's disease

Researchers have been able to mobilize the brain's native stem cells to replenish a type of neuron lost in Huntington's disease.

7 Jun 2013

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life.

7 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Researchers provide insights into potential therapeutic approaches to Down syndrome

University of Michigan researchers have determined how a gene that is known to be defective in Down syndrome is regulated and how its dysregulation may lead to neurological defects, providing insights into potential therapeutic approaches to an aspect of the syndrome.

6 Jun 2013

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

4 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

New technique selectively represses unwanted immune reactions without disabling immune system

The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Researchers identify a new mechanism that appears to suppress tumor growth

Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anti-cancer drugs.

4 Jun 2013

NewLink Genetics announces results from two clinical studies with indoximod

NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

3 Jun 2013

Researchers reveal how disease mutations affect the stability and function of Parkin protein

Researchers at the MRC Laboratory of Molecular Biology in the United Kingdom have determined the crystal structure of Parkin, a protein found in cells that when mutated can lead to a hereditary form of Parkinson's disease.

3 Jun 2013

Spicing up fingerprints

It is most commonly used to spice up Indian cuisine, but scientists at Sheffield Hallam University have discovered turmeric could be used to help solve crimes.

From Sheffield Hallam University 3 Jun 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.

1 Jun 2013

Theoretical mathematical models offer insights into therapeutic, prevention strategies for HIV

The first few hours to days following exposure to human immunodeficiency virus can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models.

1 Jun 2013

Researchers uncover role of key protein linked to development of cancers

Virginia Commonwealth University researchers studying a key molecular player called Hsp70 that is responsible for protein homeostasis have uncovered how it binds together with another molecule responsible for intracellular energy transfer to enhance its overall activity and efficiency - details that have previously not been well understood.

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Scientists move closer to understanding HIV-1 infection

Scientists have long been unable to fully explain how infections attack the body, but now a team of researchers, including one from the University of Central Florida, has taken a step closer to understanding how the process works in HIV-1. The results mean that one day that knowledge may prevent infection.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Scientists discover new function of an enzyme that disposes of superfluous proteins

Cells have a sophisticated system to control and dispose of defective, superfluous proteins and thus to prevent damage to the body. Dr. Katrin Bagola and Professor Thomas Sommer of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch as well as Professor Michael Glickman and Professor Aaron Ciechanover of Technion, the Technical University of Israel in Haifa, have now discovered a new function of an enzyme that is involved in this vital process.

29 May 2013

Molecule News and Research

Cedars-Sinai opens Phase III clinical trial for patients with intestinal carcinoid cancer

Researchers mobilize brain's native stem cells to replenish neuron lost in Huntington's disease

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Researchers provide insights into potential therapeutic approaches to Down syndrome

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Researchers demonstrate how modified citrus pectin works against cancer

New technique selectively represses unwanted immune reactions without disabling immune system

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Researchers identify a new mechanism that appears to suppress tumor growth

NewLink Genetics announces results from two clinical studies with indoximod

Researchers reveal how disease mutations affect the stability and function of Parkin protein

Spicing up fingerprints

Researchers discover potential biomarkers to identify patients with head and neck cancer

Theoretical mathematical models offer insights into therapeutic, prevention strategies for HIV

Researchers uncover role of key protein linked to development of cancers

GLYX-13 drug induces antidepressant results without street drug side effects

Scientists move closer to understanding HIV-1 infection

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Scientists discover new function of an enzyme that disposes of superfluous proteins

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News